Cybin (CYBN) said Tuesday that the US Patent and Trademark Office has granted the company a patent in support of its CYB004 deuterated dimethyltryptamine program for the treatment of generalized anxiety disorder.
The patent, which is expected to provide exclusivity until 2040, includes its claims to novel formulations of dimethyltryptamine and deuterated isotopologues for intramuscular injection, the company said.
Shares of the biotech firm fell by more than 1% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.